Coronavirus Covid-19 Information

BMS CA209-7FL

A randomized, multicenter, double-blind, placebo-controlled phase 3 Study of Nivolumab Versus Placebo in Combination With neoadjuvant chemotherapy and adjuvant endocrine therapy in the treatment of high-risk, Stage II-III estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer
Study Phase: Phase 3
Principal Investigator: Dr Sue Sukor
Further information

GSK 213831 ZEST

A Randomized Phase 3 Double-Blinded Study Comparing Efficacy of Niraparib to Placebo in Participants with Either HER2-Negative BRCA-Mutated or Triple-Negative Breast Cancer with Molecular Disease Based on Presence of Circulating Tumor DNA after Definitive Therapy
Study Phase: Phase 3
Principal Investigator: Dr Sue Sukor
Further information

MK3475-756 (KEYNOTE-756)

A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2–) Breast Cancer (KEYNOTE-756)
Study Phase: Phase 3
Principal Investigator: Dr Sue Sukor
Further information

Enquire about a Cancer Clinical Trial

If you would like more information on Cancer Clinical Trials you can contact us.

Make an enquiry